Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.440
+0.370 (17.87%)
At close: Mar 23, 2026, 4:00 PM EDT
2.450
+0.010 (0.41%)
Pre-market: Mar 24, 2026, 8:45 AM EDT

Allogene Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
-0.020.10.16114.09
Revenue Growth (YoY)
--76.84%-39.10%-99.86%-
Gross Profit
-0.020.10.16114.09
Selling, General & Admin
56.7865.2171.6779.3174.11
Research & Development
150.15192.3242.91256.39220.18
Other Operating Expenses
2.3815.7213.25--
Total Operating Expenses
209.32273.22327.83335.69294.28
Operating Income
-209.32-273.2-327.74-335.54-180.19
Interest Income
19.2920.1518.314.571.71
Interest Expense
-1.08-0.18---
Other Non-Operating Income (Expense)
0.22-3.92-17.84-9.44-3.57
Total Non-Operating Income (Expense)
18.4316.050.47-4.88-1.86
Pretax Income
-190.89-257.15-327.27-340.41-182.05
Provision for Income Taxes
--0.44---
Net Income
-190.89-257.59-327.27-340.41-182.05
Net Income to Common
-190.89-257.59-327.27-340.41-182.05
Shares Outstanding (Basic)
221195157143136
Shares Outstanding (Diluted)
221195157143136
Shares Change (YoY)
13.25%24.14%9.63%5.39%12.84%
EPS (Basic)
-0.87-1.32-2.09-2.38-1.34
EPS (Diluted)
-0.87-1.32-2.09-2.38-1.34
Free Cash Flow
-149.63-200.99-239.25-225.71-206.26
Free Cash Flow Per Share
-0.68-1.03-1.52-1.58-1.52
Gross Margin
-100.00%100.00%100.00%100.00%
Operating Margin
--1241813.64%-344986.32%-215087.18%-157.94%
Profit Margin
--1166836.36%-344489.47%-218214.10%-159.57%
FCF Margin
--913609.09%-251841.05%-144685.90%-180.79%
EBITDA
-196.96-259.56-313.54-321.24-169.74
EBITDA Margin
--1179818.18%-330040.00%-205923.72%-148.78%
EBIT
-209.32-273.2-327.74-335.54-180.19
EBIT Margin
--1241813.64%-344986.32%-215087.18%-157.94%
Effective Tax Rate
0.00%0.17%0.00%0.00%0.00%
Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q